IP Library › Granted Patent US 12,084,654
Granted Patent B2
US 12,084,654 · App. 18/160,804 · Granted Sep 10, 2024

Methods for using transcription-dependent directed evolution of AAV capsids

Inventors: Hiroyuki Nakai (Portland, OR); Samuel Huang (Portland, OR); Kei Adachi (Portland, OR)
Assignee: Oregon Health & Science University
C12N15/11C12N7/00C12N15/1082C12N15/86C12N2310/11C12N2320/33C12N2750/14122C12N2750/14123C12N2750/14142C12N2750/14145C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,084,654
App. No.
18/160,804
Granted
Sep 10, 2024
Kind
B2
Abstract

Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods.

Claims (12)

1. An adeno-associated virus serotype 9 (AAV9) capsid protein comprising an amino acid insertion within loop 8, wherein the amino acid insertion comprises SEQ ID NO: 128, and wherein the AAV9 capsid protein without the amino acid insertion comprises 90% sequence identity to SEQ ID NO: 221.

2. The AAV9 capsid protein of claim 1 , wherein the AAV9 capsid protein comprises a N272A mutation.

3. The AAV9 capsid protein of claim 1 , wherein the AAV9 capsid protein comprises SEQ ID NO: 221.

4. The AAV9 capsid protein of claim 1 , wherein the AAV9 capsid protein comprises SEQ ID NO: 222.

5. The AAV9 capsid protein of claim 1 wherein the amino acid insertion within loop 8 comprises a substitution of position 588 of SEQ ID NO: 221 with the amino acid insertion.

6. The AAV9 capsid protein of claim 1 , wherein the amino acid insertion further comprises a linker.

7. A nucleic acid molecule encoding an adeno-associated virus serotype 9 (AAV9) capsid protein comprising an amino acid insertion within loop 8 of the AAV9 capsid protein, wherein the amino acid insertion comprises SEQ ID NO: 128, and wherein the AAV9 capsid protein without the amino acid insertion comprises 90% sequence identity to SEQ ID NO: 221.

8. The nucleic acid molecule of claim 7 , wherein the AAV9 capsid protein comprises a N272A mutation.

9. The nucleic acid molecule of claim 7 , wherein the AAV9 capsid protein comprises SEQ ID NO: 221.

10. The nucleic acid molecule of claim 7 , wherein the AAV9 capsid protein comprises SEQ ID NO: 222.

11. The nucleic acid molecule of claim 7 , wherein the amino acid insertion within loop 8 comprises a substitution of position 588 of SEQ ID NO: 221 with the amino acid insertion.

12. The nucleic acid molecule of claim 7 , wherein the amino acid insertion further comprises a linker.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2023
From: NAKAI, HIROYUKI; HUANG, SAMUEL; ADACHI, KEI
To: OREGON HEALTH & SCIENCE UNIVERSITY
Reel/Frame 062537/0167 →
Continuity (5)
Continuation 17822111 · Aug 24, 2022
Continuation 17337341 · Jun 2, 2021
Continuation PCTUS2020016273 · Jan 31, 2020
Provisional Application 62799603 · Jan 31, 2019
Related Publication 20230287405A1 · Sep 14, 2023
Cited By (2)
US 12,467,046 US 12,630,842